You are here

SARC001

Completed
Phase 2 Trial of Imatinib Mesylate (Gleevec) in patients with soft tissue and bone sarcomas: a multi-disciplinary trial
Type of Sarcoma: 
Ewing's Family (including PNET), OsteosarcomaSynovial Sarcoma, Leiomyosarcoma, Rhabdomyosarcoma (including alveolar, embryonal and pleomorphic), Liposarcoma (all variants), Malignant Fibrous Histiocytoma, Peripheral Nerve Sheath (including MPNST, neurofibrosarcoma, schwannoma), Fibrosarcoma, Angiosarcoma (all variants), Desmoid Tumor, GI Stromal (c-kit negative only)
Drug: 
Imatinib Mesylate (Gleevec)
Accrual Status: 
Closed
Overall Study Principal Investigator: 
Laurence H. Baker, DO
University of Michigan

For more information about this trial and open sites: